12.79
+0.29(+2.32%)
Currency In USD
| Previous Close | 12.5 |
| Open | 12.36 |
| Day High | 13.07 |
| Day Low | 12.29 |
| 52-Week High | 17 |
| 52-Week Low | 4.92 |
| Volume | 400,440 |
| Average Volume | 819,288 |
| Market Cap | 963.6M |
| PE | -4.21 |
| EPS | -3.04 |
| Moving Average 50 Days | 12.25 |
| Moving Average 200 Days | 9.63 |
| Change | 0.29 |
If you invested $1000 in Replimune Group, Inc. (REPL) since IPO date, it would be worth $843.67 as of December 27, 2024 at a share price of $12.79. Whereas If you bought $1000 worth of Replimune Group, Inc. (REPL) shares 5 years ago, it would be worth $827.3 as of December 27, 2024 at a share price of $12.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 23, 2024 1:00 PM GMT
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management te
Replimune Announces Pricing of Upsized Public Offering
GlobeNewswire Inc.
Nov 26, 2024 4:55 AM GMT
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 sh
Replimune Announces Proposed Public Offering
GlobeNewswire Inc.
Nov 25, 2024 12:09 PM GMT
WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million